Search 

Gay Yuyitung is the Executive Director of the McMaster Industry Liaison Office (MILO), which is the technology transfer office for McMaster University and its affiliated hospitals (Hamilton Health Sciences and St. Joseph's Healthcare). Recently, MILO has been successful in supporting start-ups raise capital and move from pre-clinical to clinical studies. Some recent examples of biotechs based on McMaster, HHS, or SJH research include Triumvira, Exerkine, Turnstone, Advanced Theranostics, and Attwill Canada.
MILO would be interested in speaking to potetial investors and partners for opportunities in medical diagnostics, ophthalmic drug delivery platforms, and antibiotic resistant therapeutics. 

Prior to joining the NRC, Dr.Houle had spent 14 years leading business, corporate and product development activities in private and public biotechnology firms at various stages of development from University spin-offs to more established companies. Most recently, as COO of Kapplex, he guided the company through its initial spin-out of the University into a full-fledged funded start-up. Prior to Kapplex, Dr. Houle held a leadership role in product and business development at Axela, a company in the field of multiplexed biomarker detection, leading the successful launch of several products. Dr. Houle began his industrial career at SYNX Pharma, a proteomics and diagnostics company, where he sought out, structured and fostered collaborations and alliances. These activities led to a diagnostic development agreement with Ortho-Clinical Diagnostics and the eventual merger of SYNX with Nanogen Inc. JF holds a Ph.D. in Experimental Medicine from McGill University and holds several patents in the field of biomarker detection.

Dr. Fiebig is an entrepreneur and biopharma executive with over 14 years of management experience in academia, industry and not-for-profit (government) organizations.  He is the Senior Director, Strategic Programs at the Ontario Bioscience Innovation Organization (OBIO) and leads OBIO’s Capital Access Advisory Program which has received significant support from FedDev Ontario to strengthen Ontario’s cadre of investable human health technology companies, increasing high value deal flow.  Prior to his role at OBIO, Dr. Fiebig was CSO and VP of Research Programs at Ontario Genomics, a government funding organization, where he oversaw an $800M research program portfolio.  During this time he was responsible for more than 10 funding competitions, a team of research program managers, and Ontario Genomics’ strategic approach to identifying, cultivating, and raising funds for genomics and proteomics projects and platforms in Ontario.  As Senior Director, Structural Biology and Computational Chemistry at Affinium Pharmaceuticals in Toronto he led the structural biology and computational chemistry teams and a 20 FTE strategic alliance with Pfizer on structure-based drug discovery focused on infectious disease.  Prior, Dr. Fiebig founded and managed MRPharm GmbH, a fee-for-service and drug discovery biotech start-up in Frankfurt, Germany and was a lead scientist with Xencor in Los Angeles responsible for improving their automatic computational protein design platform.  Dr. Fiebig has a broad scientific background in the physical and biomedical fields. He trained at Yale University (Post Doctorate), Oxford University (Post Doctorate), University of California at San Francisco (PhD), and the Technical University Munich (undergraduate). He co-authored numerous scientific publications and holds several patents.

Dr. Arlene Yee is responsible for technology commercialization and industry engagement activities at the Industry Partnerships and Commercialization Office (IP&C) at The Hospital for Sick Children. She leads a team of professionals at the IP&C where her role includes evaluating and assessing technology disclosures, commercialization of technology opportunities, licensing, spin-off company formation, sponsored research, and industrial liaison. Her vast experience includes commercializing a variety of intellectual property from academic health science institutions, including start-up company formation and licensing.  Arlene has held previous appointments at McMaster University and the University of Guelph.  Arlene has a degree in veterinary medicine and a Masters of Science degree in microbiology from the University of Guelph. She is also a Registered Technology Transfer Professional, a designation that recognizes professionals in the tech transfer and business development areas of the profession. She is an active member of The Licensing Executive Society (LES) and The Association of University Technology Managers (AUTM).